During World Blood Cancer Day, together with many people and organizations, we show patient and professional communities about the great research which is conducted worldwide. We are grateful to be part of the innovation path towards finding new treatments for patients suffering from blood cancer. We are determined to create and implement new strategies based on Big Data technologies in Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Myelodysplastic Syndromes, Non-Hodgkin's Lymphoma, Multiple Myeloma, and Pediatric Hematologic Malignancies.
Read more about the 7 Hematologic Malignancies, the focus of HARMONY >
Read about our Research Projects >
View who are the organizations behind the HARMONY Alliance:
Receive the latest news. Click here to subscribe!
Public-private partnership for Big Data in Hematology
HARMONY and HARMONY PLUS are funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. Funding is received from the IMI 2 Joint Undertaking and is listed under grant agreement for HARMONY No. 116026 and grant agreement for HARMONY PLUS No. 945406. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
HARMONY Coordination Office
Institute of Biomedical Research of
Salamanca (IBSAL)
Salamanca, Spain
HARMONY Communications
European Hematology Association (EHA)
The Hague, The Netherlands
